N/A N=8 308nm Excimer Laser for Treatment of Fingernail Psoriasis
Nail Psoriasis
Primary: Modified NAPSI Score (Nail Psoriasis Severity Index) — 6.3; 6.0 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=21 Topical Cyclosporine Suspension for the Treatment of Brittle Nails
Brittle Nail Syndrome
Primary: • Number of Patients Receiving at Least a 1-grade Improvement in the Physicians Global Improvement Assessment (PGIA) of Two Target Nails. — 10; 11 patients
Phase 4 N=12 A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis
Psoriatic Nail · Psoriasis Vulgaris · Psoriasis
Primary: Mean Percent Change of mNAPSI (Modified Nail Area Psoriasis Severity Index) at Week 36 Compared to Baseline for All Nails. — 64.1 percentage of reduction in mNAPSI score…
Phase 4 N=22 Use of Platelet-rich Plasma (PRP) Therapy in Patients With Brittle Nail Syndrome
Nail Diseases
Primary: Physician Global Improvement Assessment (PGIA) — 5; 2; 7; 1 Fingernails
Phase 3 N=99 Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
Chronic Plaque Psoriasis · Moderate to Severe Nail Psoriasis
Primary: The Proportion of Subjects Who Achieve at Least a 75% Improvement From Baseline in Total mNAPSI at Week 28. — 0.042; 0.255 proportion of subjects — p=0.00311
N/A N=20 Real-World Evaluation of the Effect of Jublia on Nail Polish
Evaluation of Jublia on Nail Polish With Healthy Toenails
Primary: Observe Stability of Nail Polish as Evidenced by Serial Photography With Efinaconazole Application in Terms of Days — 1.5; 5; 15; 5 days of stability
N/A N=26 Early Feasibility Study to Evaluate the Efficacy and Safety of the RenewalNail™ Plasma Treatment System in Patients With Mild to Moderate Onychomycosis (Fungal Nail)
Onychomycosis Due to Trichophyton Rubrum · Onychomycosis Due to Trichophyton Mentagrophytes
Primary: Mycological Cure — 12 Participants
N/A N=5 Early Feasibility Study to Evaluate the Efficacy of the RenewalNail™ Plasma Treatment System in Patients With Onychomycosis (Fungal Nail)
Onychomycosis of Toenail · Onychomycosis
Primary: Mycological Cure — 2 Participants
Phase 3 N=23 Use of N-Acetylcysteine (NAC) in Fingernail Biting
Onychophagia
Primary: Number of Participants Enrolled Within One Year — 12; 11 Participants
Phase 4 N=20 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer
Foot Dermatoses
Primary: Percent of "in Label" Adherent Subjects — 85; 60 percentage of participants
Phase 4 N=50 Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish
Foot Dermatoses
Primary: Measurement of Antifungal Activity of Loceryl Nail Lacquer — 53.6; 53.5 Milimeter
Phase 3 N=139 PinPointe FootLaser for the Treatment of Onychomycosis
Infected Toenails · Onychomycosis
Primary: Nail Bed Clearing
Phase 3 N=31 Evaluation of the Efficacy and Safety of Indigo Naturalis Oil Extract on Psoriatic Nails
Nail Psoriasis
Primary: Change From Baseline in Single-Hand Nail Psoriasis Severity Index (NAPSI)and in the Modified Target NAPSI for the Single Most Severely Affected Nail of Each Hand at Week…
Phase 4 N=47 Nailfold Capillary Blood Flow With Latanoprost Bunod
Glaucoma, Open-Angle
Primary: NFC Blood Flow at Baseline and 15 Minutes — 72.52; 83.94; 93.01; 60.50 pL/s
N/A N=27 Treatment of Onychomycosis Using a 0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser
Onychomycosis
Primary: The Primary End Point Was the Percentage of Patients With a Negative Mycological Culture. — 12; 10 percentage of participants — p=<0.05
Phase 2 N=47 Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe Nail
Onychomycosis
Primary: Number of Participants With Negative Fungal Culture — 14; 2 Participants
Phase 2 N=30 Efficacy, Safety, and Tolerability of HTS-519 Insert in Patients With Toenail Fungus of the Big Toenail
Onychomycosis
Primary: Treatment Related Adverse Events — 22; 8 Participants
Phase 3 N=518 Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail
Onychomycosis
Primary: Efficacy Assessed by Complete Cure Rate at the End of Study (Week 52) After Treating for 24 or 48 Weeks. — 0.79; 0.78; 1.47; 0.00 Percentage of Participants
Phase 3 N=526 Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail
Onychomycosis
Primary: Efficacy Assessed by the Percentage of Participants With Complete Cure at the End of Study (Week 52) After Treating for 24 or 48 Weeks — 1.50; 0.77; 2.96; 0 Percentage…
Phase 3 N=40 Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients
Onychomycosis
Primary: Primary Endpoint - Efficacy — 4 Participants
Phase 3 N=198 Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
Moderate to Severe Nail Psoriasis
Primary: Percentage Change From Baseline in Nail Psoriasis Severity Index (NAPSI) After 16 Weeks of Treatment — -38.4; -46.1; -11.7 percent change — p=<0.0001
Phase 4 N=55 Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis
Nail Psoriasis · Nail Diseases
Primary: Lowest Effective Concentration of Intralesional Triamcinolone Acetonide for Nail Psoriasis — 2.5 mg/mL
N/A N=45 Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure
Nail Growth Cessation · Intraocular Pressure
Primary: Change From Baseline in Nail Length of Hands — 13.49; 15.10; 1.34; 1.51 mm — p=0.532
Phase 3 N=33 Comparison of Indigo Naturalis Oil Extract and Calcipotriol Solution in Treating Psoriasis
Nail Psoriasis
Primary: Change From Baseline in Single-handed Nail Psoriasis Severity Index (shNAPSI) at 24 Weeks — 27.2; 27.4; 14.4; 20.4 units on a scale
N/A N=506 Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
Moderate to Severe Plaque Psoriasis
Primary: Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) to Month 12 — -74.6 percent change
N/A N=44 Retrospective Study Chimaera Long Nail in Adult Patient
Pertrochanteric Fracture of Femur · Intertrochanteric Fracture of Femur · Subtrochanteric Fracture of Femur
Primary: Percent of Patients in Which Bone Union Has Been Achieved — 42 Participants
N/A N=105 Study of the Use of Low Level Laser Light Therapy to Treat Toenail Fungus
Onychomycosis
Primary: Proportion of Toenails Attaining 25 Percent (%) or More Increase in Clear Nail — 65 percentage of toenails
Phase 2 N=24 Restasis for Treatment of Brittle Nails
Brittle Nails
Primary: Change From Baseline in the Physician's Global Assessment (PGA) of Target Fingernails #1 and #2 — -1.4; -1.4 scores on a scale
Phase 3 N=1,029 Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis
Onychomycosis
Primary: Percentage of Participants With Complete Cure at the End of Study After Treating Participants for 48 Weeks — 1.18; 0.96 Percentage of participants
Phase 3 N=217 A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
Nail Psoriasis · Plaque Psoriasis
Primary: Percentage of Participants Achieving a Total Fingernail Modified Nail Psoriasis Severity Index (mNAPSI) 75 Response at Week 26 — 3.4; 46.6 percentage of participants…